## IN THE UNITED STATES PATENTAND TRADEMARK OFFICE

Application No.:

10/517,214

Art Unit:

Tba

Filed:

11/23/2004

Examiner:

tba

1<sup>st</sup> Inventor:

MAEKAWA, T.

Allowed:

For:

1,2-Azole Derivatives with Hypoglycemic

And Hypolipidemic Activity

Atty. Dkt. No.

3065 US0P

Paper No.:

## Notice to Comply with Sequence Listing Requirements

## MAIL STOP SEQUENCE

Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

Sir:

In reply to the Notice mailed 12/13/2005, Applicants respectfully submit a substitute written Sequence Listing for the Specification and a DOS Text CRF Sequence Listing file "3065 USOP SEQ V2.txt" on the enclosed 3.5" IBM PC/AT computer disk, with a copy of the notice.

Please substitute the Written Sequence Listing for the Sequence Listing filed with the original PCT application.

The undersigned hereby certifies that the CRF and the written Sequence Listing are the same in content. The Sequence Listing contains no new matter.

Respectfully submitted,

Dated: December 20, 2005

(847)383-3372

Mark Chao, Ph.D., Reg. No. 37,293

(847)383-3391

Elaine M. Ramesh, Ph.D., Reg. No. 43032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA